Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting

On November 6, 2026 Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported it will present data on the novel mechanism of action for CTX-10726 at the 41st Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting. CTX-10726 is currently in a Phase 1 dose-escalation study in patients in the post-checkpoint setting with multiple types of advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data highlights from the presentation include:

Novel PD-1 Cleavage Mechanism. In addition to the expected dual blockade of VEGF-A and PD-1, preclinical studies also revealed a novel mechanism of action for CTX-10726. Specifically, the multimerization of CTX-10726 facilitates the cleavage and removal of PD-1 from the surface of T cells, converting PD-1 positive T cells into PD-1 negative T cells and extending the mechanism beyond simply checkpoint blockade and angiogenesis inhibition.
VEGF-A Enhanced Potency. Adding VEGF-A increased the potency of CTX-10726 approximately ten-fold in a human immune-cell assay measuring interferon-gamma production, reducing the EC50 from 2.0 to 0.2 nM. In vitro studies showed PD-1 receptor cleavage by CTX-10726 in the presence of VEGF-A compared to PD-1 receptor internalization in the absence of VEGF-A. Neither pembrolizumab nor bevacizumab alone demonstrate comparable PD-1 cleavage. Two in vivo models further demonstrated the VEGF-A-dependent nature of PD-1 receptor cleavage by CTX-10726.
Combined Activity with CTX-471. A mouse surrogate of CTX-10726 combined with CTX-471 (CD137 agonist antibody) further enhanced anti-tumor activity in mouse models, accompanied by coordinated upregulation of chemokines, interferon-stimulated genes, and inflammatory cytokines. These changes were associated with increased immune cell recruitment and establishment of a more permissive tumor microenvironment.

"These data reveal a new and differentiated mechanism of action for CTX-10726, setting it apart in this exciting new class of therapeutics," said Thomas Schuetz, MD, PhD, Chief Executive Officer. "We believe PD-1 receptor cleavage results in more potent and potentially more durable checkpoint inhibition, which supports and explains what we saw in our earlier studies. The dependence of this mechanism on VEGF links a traditionally anti-angiogenic agent directly to checkpoint control and may enhance the activity of CTX-10726 within VEGF-A-rich tumor microenvironments. We are also encouraged by the combination results with CTX-471 in checkpoint-resistant models, supporting further investigation of these complementary approaches."

The Phase 1 multiple ascending dose-escalation study of CTX-10726 includes four dosing cohorts (0.3, 1.0, 3.0, and 10.0 mg/kg) in a 3+3 format. The multi-center study is enrolling post-checkpoint patients with a prioritized set of locally advanced, unresectable or metastatic malignancies, including renal cell carcinoma, gastroesophageal cancer, hepatocellular carcinoma, and endometrial cancer, in whom standard of care therapies have failed.

Details of the presentation are as follows:

Title: VEGF-dependent cleavage of cell surface PD-1 mediated by CTX-10726, a novel PD-1×VEGF-A bispecific antibody
Date & Time: Saturday, November 7, 2026 from 10:00 AM–2:00 MT PM and 6:00–8:10 MT PM
Poster number: 678
Location: Phoenix Convention Center – North Building – Lower Level – Exhibition Halls 4-5

A copy of the presentation materials can be accessed on the Compass website at View Source once the presentation has concluded.

About CTX-10726
CTX-10726 is a tetravalent PD-1 x VEGF-A bispecific antibody discovered and engineered at Compass. CTX-10726 is designed to synergistically deliver VEGF-A blockade and checkpoint inhibition, potentially applicable to multiple solid tumor indications. The bispecific antibody demonstrates a highly stable structure with high affinity target binding. CTX-10726 exhibits more potent PD-1 suppression and a novel mechanism of action compared with data reported for other drugs in the class.

(Press release, Compass Therapeutics, NOV 6, 2026, View Source [SID1234674424])

Immunocore reports third quarter financial results and provides a business update

On November 6, 2026 Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, reported its financial results for the third quarter ended September 30, 2026, and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A*02:01+ metastatic uveal melanoma. With TEBE-AM fully enrolled and data expected in the second quarter of 2027, we are advancing our mission to bring this therapy to even more patients," said Bahija Jallal, CEO of Immunocore. "Recently, our platform delivered two significant firsts: what we believe is the first data demonstrating clinical activity and a manageable safety profile with the combination of two T cell engagers in a solid tumor, and the first patient dosed in our tissue-specific autoimmune program for type 1 diabetes."

Third Quarter Highlights (including post-period)

Financial Results

For the third quarter ended September 30, 2026, total net product revenue (or ‘net sales’) arising from the sales of KIMMTRAK was $102.2 million, compared to $103.7 million for the same period in 2025. Q3 2026 sales were $62.2 million in the United States, $34.9 million in Europe, and $5.1 million in international regions. Revenue from net product sales compared to Q3 of 2025 was impacted by (i) United States wholesaler stocking that occurred in Q2 of 2026 and (ii) one additional week of sales in the U.S. in Q3 2025. Normalizing for the two US-related items above, underlying revenue growth for this quarter was approximately 10%, as compared to Q3 2025.

For the nine months ended September 30, 2026, net sales of KIMMTRAK were $324.8 million, compared to $295.5 million for the same period in 2025. For the nine months ended September 30, 2026, sales were $204.6 million in the United States, $103.5 million in Europe and $16.7 million in international regions. The increase in net product sales was due to continued growth in the United States, Europe and international regions.

Research and development (R&D) expenses for Q3 2026 were $74.7 million, compared to $70.6 million for Q3 2025. This increase was primarily due to advancement of our clinical programs, including our three Phase 3 trials.

Selling, general and administrative (SG&A) expenses for Q3 2026 were $40.5 million, compared to $39.8 million for Q3 2025.

Net loss for Q3 2026 was $14.2 million ($0.28 loss per share) compared to $0.2 million ($0.00 loss per share) for Q3 2025. Net loss for the nine months ended September 30, 2026, was $2.1 million ($0.04 loss per share) compared to $5.5 million ($0.11 loss per share) for the nine months ended September 30, 2025.

Cash, cash equivalents and marketable securities were $901.3 million as of September 30, 2026, as compared to $864.2 million as of December 31, 2025. The Company expects to pay, in the fourth quarter of 2026, approximately $120 million in sales-related rebate accruals.

KIMMTRAK

The Company’s lead product, KIMMTRAK, is approved in 39 countries and has been launched in over 30 countries globally to date for HLA-A*02:01 positive people with unresectable or metastatic uveal melanoma (mUM). KIMMTRAK continues to be the standard of care in all major markets where it is launched.

The Company sees three key growth areas for KIMMTRAK as it plans to expand patient reach, including continued US community and global market penetration in mUM, the potential expansion into 2L+ advanced cutaneous melanoma (CM), and the potential expansion into adjuvant uveal melanoma.

Metastatic uveal melanoma

The five-year overall survival (OS) data from the Phase 3 trial of KIMMTRAK in patients with unresectable or mUM, which were presented at the AACR (Free AACR Whitepaper) 2026 meeting, have been accepted by the European Medicines Agency for inclusion in the European SmPC (Summary of Product Characteristics). This addition to the SmPC will allow the Company to engage more broadly with healthcare professionals in the region about the data.
The Company received the International Prix Galien 2026 for KIMMTRAK in the orphan/rare diseases category. This is the fifth Prix Galien awarded to KIMMTRAK.

2L+ advanced cutaneous melanoma

The registrational Phase 3 TEBE-AM trial, evaluating tebentafusp as monotherapy and in combination with pembrolizumab, versus a control arm in patients with previously treated advanced CM, has achieved its target enrollment of 540 patients. The trial is event-driven and topline overall survival data is expected in the second quarter of 2027.
There is great unmet need in second- and later-line CM, with no therapy, to date, having shown an OS improvement following progression on checkpoint inhibitors in a randomized clinical trial. The Company estimates there are up to 4,000 HLA-A*02:01 positive, previously treated, advanced CM patients in the US and Europe.
Adjuvant uveal (or ocular) melanoma

The European Organisation for Research and Treatment of Cancer (EORTC) is enrolling patients in the Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM) in Europe and the United States.
The Company estimates the HLA-A*02:01 positive, high-risk adjuvant uveal melanoma patient population could represent up to 1,200 patients in the US and Europe.
PRAME portfolio

Brenetafusp is the Company’s lead PRAME-A02 ImmTAC bispecific candidate. Brenetafusp is being evaluated in combination with nivolumab in a Phase 3 registrational trial (PRISM-MEL-301) in patients with first-line, advanced cutaneous melanoma, and in a Phase 1/2 clinical trial as monotherapy and in combination across multiple solid tumors, including ovarian cancer, uveal melanoma, and non-small cell lung cancer (NSCLC).

PRISM-MEL-301 – First PRAME Phase 3 clinical trial with brenetafusp in first-line advanced cutaneous melanoma

The Company continues enrollment of HLA-A*02:01 positive, first-line, advanced or metastatic cutaneous melanoma patients with 1:1 randomization to brenetafusp 160 mcg + nivolumab or a control arm of either nivolumab or nivolumab + relatlimab.
Despite approved therapies, there remains an unmet need for improved progression-free survival and OS in the first-line setting, where there is the potential to address an estimated 10,000 HLA-A*02:01 positive patients across the US and Europe.
Phase 1/2 clinical trials of brenetafusp and IMC-P115C (PRAME-A02 Half-Life Extended) in multiple solid tumors

Combination of KIMMTRAK and brenetafusp in metastatic uveal melanoma

As of June 2026, 22 HLA-A*02:01 positive adult patients with mUM received brenetafusp monotherapy at clinically active doses and 26 received the combination of KIMMTRAK and brenetafusp.
Among the 16 evaluable patients who received brenetafusp monotherapy in the second-line or later setting, overall response rate (ORR) was 19%, median duration of response (mDoR) was 14.5 months, median progression-free survival (mPFS) was 4.2 months, and median OS was 20.3 months.
Across the 17 evaluable first-line patients who received the combination, ORR was 29%, mDoR was 24.1 months, mPFS was 8.1 months, and median OS was not yet reached with 29 months of follow-up and 10 patients still on study. The two-year OS rate was 70%.
The most common brenetafusp monotherapy treatment-related adverse events (TRAEs) were reversible and manageable cytokine release syndrome (CRS) (73%) and rash (50%) consistent with the molecule’s mechanism of action. Grade 3/4 TRAEs were primarily transient lymphocyte decrease which resolved without intervention.
Combination regimens were generally well-tolerated. The most common TRAEs were Grade 1/2 CRS and rash (77% each). These attenuated over time with no Grade ≥3 CRS reported. No TRAE led to discontinuation or death.
The Company will present these data in a poster today at 10:00 a.m. MST / 12:00 p.m. ET and in an oral session, Saturday, November 7 at 1:45 p.m. MST / 3:45 p.m. ET, at the 2026 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting.
The Company believes these are the first data showing clinical activity and a manageable safety profile for a combination of two T cell engagers in a solid tumor.
Based on these data, the Company is planning to start DUET-UVEAL, a randomized Phase 2/3 trial, to evaluate the combination for the treatment of HLA-A*02:01-positive patients with mUM.
Brenetafusp in other tumors and IMC-P115C

After observing an initial brenetafusp monotherapy signal in platinum-resistant ovarian cancer (PROC), the Company is evaluating, as part of an ongoing Phase 1/2 trial, combination therapy with bevacizumab in earlier lines, including platinum-sensitive ovarian cancer (PSOC). In the same trial, the Company continues signal detection across multiple metastatic non-small cell lung cancer (NSCLC) cohorts, including combinations with standards of care in earlier-line NSCLC.
The Company expects to present clinical data for brenetafusp from the ovarian and lung cohorts in the Phase 1/2 trial at a medical conference later this year.
In parallel, the Company is continuing to enroll patients in the Phase 1 dose escalation trial evaluating IMC-P115C in patients with multiple solid tumors.

ImmTAV candidates for a functional cure in infectious diseases

The Company’s bispecific TCR technology platform has the potential to offer a new approach for the treatment of certain chronic infections by eliminating the remaining virus in circulation after the patients stop taking their antiviral medication – known as a ‘functional cure’. The Company is studying an investigational candidate for people living with human immunodeficiency virus (HIV).

Phase 1/2 trial of IMC-M113V (Gag-A02) for people living with HIV

In July 2026, at the International AIDS Society meeting in Rio de Janeiro, the Company presented translational data, from the first three cohorts of the multiple ascending dose (MAD) part of the Phase 1/2 trial, demonstrating that IMC-M113V induces robust type I and II interferon-associated immune programs, with stronger induction in participants who maintained viral control after treatment interruption.
The data also showed that, in addition to previously demonstrated direct killing of HIV-infected cells, IMC-M113V redirection of T cells results in induction of a robust interferon-associated immune program that may contribute to post-treatment viral control.
The Company completed enrollment of additional patients at higher dose cohorts, up to 1200 mcg, as part of the MAD portion of the Phase 1/2 trial. Analysis of the new data is ongoing with results planned to be shared early next year.

Tissue-specific down modulation of the immune system for autoimmune diseases
The key differentiator of the ImmTAAI platform is down modulation of the immune system in a tissue-specific manner. The candidates achieve this by suppressing pathogenic T cells via PD1 receptor agonism only when tethered to the target tissue.

The Company recently announced that the first person with type 1 diabetes has been dosed in the Phase 1 trial of IMC-S118AI, its first tissue-specific autoimmune candidate.
IMC-S118AI is designed to bind preproinsulin on beta cells of the pancreas and deliver a PD-1 agonist signal to nearby auto-reactive T cells, thereby protecting the pancreatic beta cells from T cell attack, preserving beta cell mass, and avoiding systemic immune suppression.
The Company plans to file a clinical trial application (CTA) or investigational new drug (IND) application before the end of the year for its second autoimmune program, IMC-U120AI (CD1a x PD1), which is designed to target a variety of dermatological diseases including atopic dermatitis.

(Press release, Immunocore, NOV 6, 2026, View Source [SID1234674391])

OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026

On November 4, 2026 OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer, neurological and immunological diseases, reported encouraging Phase 1/2 results for cesalatamig (AI-081), its investigational PD-1/VEGF bispecific antibody, as monotherapy in patients with PD-(L)1-resistant/refractory non-small cell lung cancer (NSCLC). The findings will be presented in a late-breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Results reported in the SITC (Free SITC Whitepaper) abstract were derived from a pooled analysis of the global, multicenter, open-label BiPAVE-001 and BiPAVE-001 CN Phase 1/2 studies. As of July 31, 2026, the safety population included 103 patients with NSCLC who had received at least one dose of cesalatamig monotherapy at 1, 3, 10 or 20 mg/kg Q3W. Of these patients, 77 (75%) had non-squamous histology, 25 (24%) had squamous histology and one had unknown histology. 77% of patients had a baseline ECOG performance status of 1. The median number of prior therapy lines was two, and 42% of patients had received three or more prior lines. The safety profile was comparable between patients with squamous and non-squamous histology. The cesalatamig monotherapy is well tolerated at all dose levels.

Among 55 efficacy-evaluable patients with PD-(L)1 resistant/refractory NSCLC, cesalatamig monotherapy demonstrated dose-dependent antitumor activity. At 1 mg/kg (10 patients), 3 mg/kg (24 patients) and 10 mg/kg (21 patients) Q3W, investigator-assessed objective response rates (ORR) were 10%, 21% and 33%, respectively; disease control rates (DCR) were 40%, 67% and 90%, respectively. Responses to cesalatamig monotherapy were observed across PD-L1 expression levels. Exposure-response analyses support selection of 10 mg/kg Q3W as the dose for further development.

"Patients whose NSCLC progresses after immunotherapy and chemotherapy have limited effective treatment options," said Kai He, MD, PhD, principal investigator of the US BiPAVE-001 trial and the presenter of this study. "The responses and disease control observed with cesalatamig monotherapy are encouraging. Together with the manageable safety profile observed in these studies, these findings support further clinical evaluation in this setting."

"These findings strengthen the rationale for advancing cesalatamig monotherapy in previously treated NSCLC," said Yang Liu, PhD, Co-founder, Chief Executive Officer and Chief Scientific Officer of OncoC4. "The clinical results and exposure-response analyses support the selection of 10 mg/kg every three weeks as the dose for our planned pivotal study and provide a clear path forward for the continued development of cesalatamig in this setting."

Presentation Information

Title: Safety and Efficacy of Cesalatamig, a Novel PD-1/VEGF Bispecific Antibody, as Monotherapy in PD-(L)1–Resistant/Refractory NSCLC: Results from Global, Multicenter, Open-Label Phase 1/2 Studies

Abstract: #1187 (late-breaking oral presentation)
Presenter: Kai He, MD, PhD
Date: November 7, 2026
Meeting: 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), Phoenix, Arizona
Session: Clinical Oral Abstract Session 2, beginning at 1:45 PM MST

About Cesalatamig

Cesalatamig (AI-081) is an investigational, tetravalent PD-1/VEGF bispecific antibody designed to promote cooperative interactions between PD-1 and VEGF blockade in the tumor microenvironment. It combines high-affinity binding with Fc-silencing modifications intended to avoid depletion of PD-1-positive effector T cells. Cesalatamig is being evaluated as monotherapy and in combination with standard of care in the ongoing BiPAVE-001 clinical program. In September 2026, the U.S. FDA granted cesalatamig Fast Track designation for NSCLC that has progressed after concurrent or sequential PD-(L)1-targeted immunotherapy and platinum-based chemotherapy.

About BiPAVE-001

BiPAVE-001 (NCT06635785) and BiPAVE-001 CN (CTR20253261) are ongoing Phase 1/2 clinical trials evaluating the safety, pharmacokinetics, and efficacy of cesalatamig (AI-081), a bispecific antibody targeting PD-1 and VEGF, in patients with advanced solid tumors. OncoC4 is conducting these studies in the United States and China, respectively. Part A is the first-in-human Phase 1 dose-escalation and dose-expansion portion in patients with advanced solid tumors. Part B is the Phase 2 portion and includes dose-optimization trials evaluating AI-081 as monotherapy or in combination with standard of care in selected indications.

(Press release, OncoC4, NOV 6, 2026, View Source [SID1234674409])

Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026

On November 6, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported compelling preclinical data demonstrating that atebimetinib, the Company’s novel Deep Cyclic Inhibitor of MEK, enhanced the activity of PD-1 checkpoint blockade in RAS-mutant colorectal and lung cancer models, including a 50% durable complete regression rate in a colorectal model and a 1.8-fold median survival improvement with a triple combination in a lung model. The data are being presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Curing 50% of mice in one tumor model and nearly doubling median overall survival in another are both incredibly exciting. These data add to the body of preclinical evidence that combining a pulsatile inhibitor of MEK with immunotherapy may lead to enhanced activity," said Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer of Immuneering. "The ultimate test of this hypothesis will be to show it in patients, and it starts very soon: we expect to dose the first patient by the end of the year in our Phase 2 clinical trial of atebimetinib in combination with anti-PD-1 and chemotherapy in first-line RAS-mutant NSCLC patients."

In the CT-26 syngeneic mouse model of colorectal cancer, both the 75 mg/kg and 125 mg/kg atebimetinib plus anti-PD-1 groups achieved complete tumor regression in 6 of 12 mice (50%) per group, with no regrowth even after treatment discontinuation. Vehicle-treated animals had median survival of 21 days, while anti-PD-1 alone resulted in median survival of 29 days and atebimetinib monotherapy extended median survival dose-dependently from 28 to 41.5 days. In contrast, median survival was not reached in the atebimetinib plus anti-PD-1 combination groups, which outperformed the single-agent arms (P<0.0001 versus vehicle for nearly all combinations).

In the LL2 syngeneic lung cancer model, a PD-1-cold model unresponsive to anti-PD-1 monotherapy, atebimetinib demonstrated enhanced antitumor activity in combination with anti-PD-1 and platinum-doublet chemotherapy. At 125 mg/kg BID, atebimetinib plus anti-PD-1, carboplatin and pemetrexed extended median survival to 25 days, compared with 14 days for anti-PD-1 plus chemotherapy alone, representing a 1.8-fold improvement. All 12 mice receiving the triple combination were alive at Day 18, compared with none of the 12 mice receiving anti-PD-1 plus chemotherapy alone. These data support further clinical investigation of this combination in first-line RAS-mutant non-small cell lung cancer (NSCLC).

Presentation Details:
Title: "Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the pulsatile MEK inhibitor, Atebimetinib, enhances PD-1 checkpoint blockade in RAS mutant tumors."
Abstract: #377
Presenting Author: Amy E. Axel, Immuneering Corporation
Presentation: Friday, November 6, 2026

Following presentation, the poster will be available on the publications section of Immuneering’s website at View Source

(Press release, Immuneering, NOV 6, 2026, https://www.globenewswire.com/news-release/2026/11/06/3397545/0/en/atebimetinib-combinations-with-anti-pd1-cured-50-of-mice-in-a-ras-mutant-colorectal-cancer-model-and-nearly-doubled-survival-in-a-ras-mutant-lung-cancer-model-new-data-presented-at.html [SID1234674425])

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

On November 6, 2026 Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, reported data from its Phase 1/2 trial evaluating brenetafusp alone and in combination with KIMMTRAK in HLA-A*02:01-positive patients with metastatic uveal melanoma (mUM), in a poster session at the 2026 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting. The data will also be presented in an oral session on Saturday, November 7, at 3:45 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KIMMTRAK and brenetafusp are ImmTAC molecules targeting gp100 and PRAME, respectively, with PRAME representing an established negative prognostic factor in mUM. KIMMTRAK is the first bispecific T cell receptor therapy to demonstrate survival benefit in a solid tumor and is the standard of care for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma. Brenetafusp is an investigational candidate being evaluated in a range of tumors, including first-line cutaneous melanoma in the PRISM-MEL-301 Phase 3 trial. Adding brenetafusp to KIMMTRAK tests the hypothesis of whether the combination may improve outcomes in patients with HLA-A*02:01-positive mUM by increasing target engagement and enhancing T cell-mediated tumor killing.

"Immunocore continues to lead bispecific T cell engager innovation, having demonstrated the first overall survival benefit in metastatic uveal melanoma. We are now seeing the synergistic potential of combining two clinically active ImmTAC therapies. The 1- and 2-year overall survival data could be practice-changing, and I look forward to evaluating this combination in a randomized trial for patients with metastatic uveal melanoma," said Dr. Omid Hamid, Chief of Research & Immuno-Oncology, Co-Director, Cutaneous Malignancy Program at The Angeles Clinic & Research Institute.

"These encouraging Phase 1 data suggest combining brenetafusp with tebentafusp may offer a meaningful new option for HLA-A*02:01-positive patients with metastatic uveal melanoma," said Dr. Mohammed Dar, Executive Vice President, Clinical Development and Chief Medical Officer of Immunocore. "Building on our leadership with KIMMTRAK, we believe that targeting both gp100 and PRAME – a combined ImmTAC approach – offers the potential to deliver an even greater benefit for HLA-A*02:01-positive patients."

At the June 2026 data cut-off, 22 patients with mUM had received clinically active doses of brenetafusp monotherapy and 26 had received brenetafusp plus tebentafusp. The Company believes that this is the first data showing clinical activity and a manageable safety profile for a combination of two T cell engagers in a solid tumor.

Across the 17 evaluable first-line patients who received the combination, overall response rate (ORR) was 29% with a median duration of response (mDoR) of 24.1 months. The disease control rate (DCR) was 71% and median progression-free survival (mPFS) was 8.1 months. At the data cut-off, median overall survival (mOS) had not been reached at a median follow-up of 29 months. OS rates were 88% at one year and 70% at two years with 10 of the 17 patients remaining on study. The majority of patients with OS >2 years (64%; 7 out of 11) had received only the brenetafusp and tebentafusp combination.

In the 16 evaluable patients who received brenetafusp monotherapy in the second-line or later setting, ORR was 19%, mDoR 14.5 months, DCR 63%, mPFS 4.2 months, and mOS 20.3 months. OS rates were 63% at one year and 31% at two years.

The safety profile of brenetafusp as monotherapy and in combination with tebentafusp was generally well tolerated and consistent with that observed for the individual agents, with no new safety signals reported. The most frequent treatment-related adverse event (TRAE) was reversible and manageable cytokine release syndrome (CRS), observed in 77% of combination patients and 73% of monotherapy patients, with the majority being Grade 1 or 2 (no Grade 3/4 CRS for the combination and 5% Grade 3 CRS for brenetafusp monotherapy). Grade 3 or 4 TRAEs were reported in 38% of combination patients and 41% of monotherapy patients, with the most frequent being transient lymphocyte count decrease that resolved without intervention. No TRAE led to discontinuation or death in either group.

The data also demonstrated molecular responses for the combination. Out of the nine patients who were evaluable for ctDNA response, eight (89%) had a molecular response, and four (44%) achieved ctDNA clearance.

The Company is planning to start DUET-UVEAL, a randomized Phase 2/3 trial, to further evaluate the combination for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

The data presented at SITC (Free SITC Whitepaper) come from an ongoing Phase 1/2 trial (NCT04262466; EudraCT 2019-004046-16) evaluating brenetafusp as monotherapy as well as in combination across a number of solid tumors, including HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma. Brenetafusp and tebentafusp were administered by weekly intravenous infusion with step-up dosing.

Presentation details

Title: Phase 1 evaluation of brenetafusp alone and in combination with tebentafusp in metastatic uveal melanoma (Abstract number: 1177)

Poster session: Poster Hall
Date and Time: Friday, November 6, 2026, 10:00 a.m. MST / 12:00 p.m. EST

Clinical oral abstract session: Session 2
Date and Time: Saturday, November 7, 2026, 1:45 p.m. MST / 3:45 p.m. EST

(Press release, Immunocore, NOV 6, 2026, View Source [SID1234674392])